These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

664 related articles for article (PubMed ID: 18559536)

  • 1. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response.
    Gauvrit A; Brandler S; Sapede-Peroz C; Boisgerault N; Tangy F; Gregoire M
    Cancer Res; 2008 Jun; 68(12):4882-92. PubMed ID: 18559536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme.
    Phuong LK; Allen C; Peng KW; Giannini C; Greiner S; TenEyck CJ; Mishra PK; Macura SI; Russell SJ; Galanis EC
    Cancer Res; 2003 May; 63(10):2462-9. PubMed ID: 12750267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma.
    Blechacz B; Splinter PL; Greiner S; Myers R; Peng KW; Federspiel MJ; Russell SJ; LaRusso NF
    Hepatology; 2006 Dec; 44(6):1465-77. PubMed ID: 17133484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells.
    Guillerme JB; Boisgerault N; Roulois D; Ménager J; Combredet C; Tangy F; Fonteneau JF; Gregoire M
    Clin Cancer Res; 2013 Mar; 19(5):1147-58. PubMed ID: 23339127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus.
    Anderson BD; Nakamura T; Russell SJ; Peng KW
    Cancer Res; 2004 Jul; 64(14):4919-26. PubMed ID: 15256464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measles virus targets DC-SIGN to enhance dendritic cell infection.
    de Witte L; Abt M; Schneider-Schaulies S; van Kooyk Y; Geijtenbeek TB
    J Virol; 2006 Apr; 80(7):3477-86. PubMed ID: 16537615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measles virus-induced promotion of dendritic cell maturation by soluble mediators does not overcome the immunosuppressive activity of viral glycoproteins on the cell surface.
    Klagge IM; ter Meulen V; Schneider-Schaulies S
    Eur J Immunol; 2000 Oct; 30(10):2741-50. PubMed ID: 11069053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
    May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity.
    Allen C; Vongpunsawad S; Nakamura T; James CD; Schroeder M; Cattaneo R; Giannini C; Krempski J; Peng KW; Goble JM; Uhm JH; Russell SJ; Galanis E
    Cancer Res; 2006 Dec; 66(24):11840-50. PubMed ID: 17178881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer.
    McDonald CJ; Erlichman C; Ingle JN; Rosales GA; Allen C; Greiner SM; Harvey ME; Zollman PJ; Russell SJ; Galanis E
    Breast Cancer Res Treat; 2006 Sep; 99(2):177-84. PubMed ID: 16642271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme.
    Liu C; Sarkaria JN; Petell CA; Paraskevakou G; Zollman PJ; Schroeder M; Carlson B; Decker PA; Wu W; James CD; Russell SJ; Galanis E
    Clin Cancer Res; 2007 Dec; 13(23):7155-65. PubMed ID: 18056196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response.
    Achard C; Boisgerault N; Delaunay T; Roulois D; Nedellec S; Royer PJ; Pain M; Combredet C; Mesel-Lemoine M; Cellerin L; Magnan A; Tangy F; Grégoire M; Fonteneau JF
    Oncotarget; 2015 Dec; 6(42):44892-904. PubMed ID: 26539644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.
    Hasegawa K; Pham L; O'Connor MK; Federspiel MJ; Russell SJ; Peng KW
    Clin Cancer Res; 2006 Mar; 12(6):1868-75. PubMed ID: 16551872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic measles virus targets high CD46 expression on multiple myeloma cells.
    Ong HT; Timm MM; Greipp PR; Witzig TE; Dispenzieri A; Russell SJ; Peng KW
    Exp Hematol; 2006 Jun; 34(6):713-20. PubMed ID: 16728275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model.
    Iankov ID; Msaouel P; Allen C; Federspiel MJ; Bulur PA; Dietz AB; Gastineau D; Ikeda Y; Ingle JN; Russell SJ; Galanis E
    Breast Cancer Res Treat; 2010 Aug; 122(3):745-54. PubMed ID: 19894113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted release of oncolytic measles virus by blood outgrowth endothelial cells in situ inhibits orthotopic gliomas.
    Wei J; Wahl J; Nakamura T; Stiller D; Mertens T; Debatin KM; Beltinger C
    Gene Ther; 2007 Nov; 14(22):1573-86. PubMed ID: 17898797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraperitoneal therapy of ovarian cancer using an engineered measles virus.
    Peng KW; TenEyck CJ; Galanis E; Kalli KR; Hartmann LC; Russell SJ
    Cancer Res; 2002 Aug; 62(16):4656-62. PubMed ID: 12183422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a dendritic cell vaccine against measles for patients following hematopoietic cell transplantation.
    Nashida Y; Kumamoto T; Azuma E; Hirayama M; Araki M; Yamada H; Dida F; Iwamoto S; Tamaki S; Ido M; Ihara T; Komada Y
    Transplantation; 2006 Oct; 82(8):1104-7. PubMed ID: 17060861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineered measles virus as a novel oncolytic therapy against prostate cancer.
    Msaouel P; Iankov ID; Allen C; Morris JC; von Messling V; Cattaneo R; Koutsilieris M; Russell SJ; Galanis E
    Prostate; 2009 Jan; 69(1):82-91. PubMed ID: 18973133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases.
    Springfeld C; von Messling V; Frenzke M; Ungerechts G; Buchholz CJ; Cattaneo R
    Cancer Res; 2006 Aug; 66(15):7694-700. PubMed ID: 16885371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.